HOYA (TSE:7741) Is Reinvesting To Multiply In Value

What are the early trends we should look for to identify a stock that could multiply in value over the long term? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. Ergo, when we looked at the ROCE trends at HOYA (TSE:7741), we liked what we saw.

Advertisement

What Is Return On Capital Employed (ROCE)?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on HOYA is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.23 = JP¥216b ÷ (JP¥1.1t - JP¥160b) (Based on the trailing twelve months to December 2023).

Thus, HOYA has an ROCE of 23%. In absolute terms that's a great return and it's even better than the Medical Equipment industry average of 11%.

Check out our latest analysis for HOYA

roce
TSE:7741 Return on Capital Employed May 14th 2024

Above you can see how the current ROCE for HOYA compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for HOYA .

So How Is HOYA's ROCE Trending?

HOYA deserves to be commended in regards to it's returns. Over the past five years, ROCE has remained relatively flat at around 23% and the business has deployed 54% more capital into its operations. Returns like this are the envy of most businesses and given it has repeatedly reinvested at these rates, that's even better. If HOYA can keep this up, we'd be very optimistic about its future.

The Key Takeaway

In summary, we're delighted to see that HOYA has been compounding returns by reinvesting at consistently high rates of return, as these are common traits of a multi-bagger. And the stock has done incredibly well with a 138% return over the last five years, so long term investors are no doubt ecstatic with that result. So even though the stock might be more "expensive" than it was before, we think the strong fundamentals warrant this stock for further research.

On the other side of ROCE, we have to consider valuation. That's why we have a FREE intrinsic value estimation for 7741 on our platform that is definitely worth checking out.

If you want to search for more stocks that have been earning high returns, check out this free list of stocks with solid balance sheets that are also earning high returns on equity.

Valuation is complex, but we're here to simplify it.

Discover if HOYA might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:7741

HOYA

A med-tech company, provides high-tech and medical products internationally.

Outstanding track record with excellent balance sheet.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5362.1% undervalued
147 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18057.2% undervalued
28 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.320.6% undervalued
15 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2450.2% undervalued
34 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

NI
niteco
TXN logo
niteco on Texas Instruments ·

Engineered for Stability. Positioned for Growth.

Fair Value:US$435.6931.0% undervalued
11 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5253 logo
MarkoVT on COVER ·

Significant headwinds will temper expectations for FY2027

Fair Value:JP¥1.91k17.8% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TH
NFLX logo
Thomas_Bayne on Netflix ·

Netflix: Why I bought again.

Fair Value:US$94.665.3% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.1% undervalued
112 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74017.4% undervalued
39 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$268.6117.2% undervalued
1187 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative